These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 925045)

  • 21. Cholera vaccines.
    Kabir S
    Lancet Infect Dis; 2007 Mar; 7(3):176-8; author reply 178. PubMed ID: 17317594
    [No Abstract]   [Full Text] [Related]  

  • 22. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
    Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasons.
    Gupta SS; Bharati K; Sur D; Khera A; Ganguly NK; Nair GB
    Indian J Med Res; 2016 May; 143(5):545-51. PubMed ID: 27487997
    [No Abstract]   [Full Text] [Related]  

  • 25. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform.
    Liao J; Smith DR; Brynjarsdóttir J; Watnick PI
    J Bacteriol; 2018 Aug; 200(15):. PubMed ID: 29483163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera.
    Ehara M; Ichinose Y; Iwami M; Utsunomiya A; Shimodori S; Kangethe SK; Neves BC; Supawat K; Nakamura S
    Microbiol Immunol; 1993; 37(9):679-88. PubMed ID: 7505875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and protective role of three formulations of oral cholera vaccine.
    Kalambaheti T; Chaisri U; Srimanote P; Pongponratn E; Chaicumpa W
    Vaccine; 1998; 16(2-3):201-7. PubMed ID: 9607031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.
    Año G; Esquisabel A; Pastor M; Talavera A; Cedré B; Fernández S; Sifontes S; Aranguren Y; Falero G; García L; Solís RL; Pedraz JL
    Vaccine; 2011 Aug; 29(34):5758-64. PubMed ID: 21683110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developments with bacterial vaccines: cholera.
    Northrup RS
    Prog Immunobiol Stand; 1971; 5():328-9. PubMed ID: 4349833
    [No Abstract]   [Full Text] [Related]  

  • 31. [Determination of Vibrio antibody titers during anti-cholera vaccination].
    Dirimci OT; Cinar V
    Turk Hij Tecr Biyol Derg (1961); 1973; 33(2-3):118-28. PubMed ID: 4807572
    [No Abstract]   [Full Text] [Related]  

  • 32. Stability of cholera and typhoid vaccines.
    Joó I; Zsidai J
    J Biol Stand; 1979; 7(4):341-8. PubMed ID: 536377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens.
    Chaicumpa W; Parairo JR; New RC; Pongponratn E; Ruangkunaporn Y; Tapchaisri P; Chongsa-nguan M
    Asian Pac J Allergy Immunol; 1990 Dec; 8(2):87-94. PubMed ID: 2091663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions.
    Adriani R; Mousavi Gargari SL; Nazarian S; Sarvary S; Noroozi N
    Vaccine; 2018 Jan; 36(2):322-330. PubMed ID: 29191736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal.
    Albert MJ; Alam K; Rahman AS; Huda S; Sack RB
    J Infect Dis; 1994 Mar; 169(3):709-10. PubMed ID: 8158063
    [No Abstract]   [Full Text] [Related]  

  • 36. Cell-wall antigens of V. cholerae and their implication in cholera immunity.
    Watanabe Y; Ganguly R
    Prog Drug Res; 1975; 19():612-22. PubMed ID: 1219915
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera.
    Bondre VP; Sinha VB; Srivastava BS
    FEMS Immunol Med Microbiol; 1997 Dec; 19(4):323-9. PubMed ID: 9537758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of deoxycholate on cholera vaccine.
    Nagy LK
    Prog Immunobiol Stand; 1971; 5():341-7. PubMed ID: 4660539
    [No Abstract]   [Full Text] [Related]  

  • 39. [Ferric ammonium citrate as virulence-enhancing agent in the toxicity test of Vibrio cholerae and the potency assay of cholera vaccine].
    Tsai MY; Lu CH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 Feb; 22(1):75-81. PubMed ID: 2791724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current developments with cholera vaccines: "Where do we go from here?".
    Finkelstein RA
    Prog Clin Biol Res; 1980; 47():133-42. PubMed ID: 7010372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.